



Cornerstone Pharmaceuticals, Inc.  
1 Duncan Drive  
Cranbury, New Jersey 08512-3629

Media Contact: Sanjeev Luther  
Cornerstone Pharmaceuticals, Inc.  
(609) 409-7050 ext. 201  
Sanjeev@Cornerstonepharma.com

### **Cornerstone Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016**

CRANBURY, NEW JERSEY (February 05, 2016) – Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the company is scheduled to present at the LEERINK Partners 5th Annual Global Healthcare Conference in New York on Wednesday, February 10, 2016 at 11:55 AM Eastern Time. Steve Carchedi, CEO for Cornerstone will present a corporate update including the latest clinical data for their lead compound CPI-613.

A copy of the presentation can be accessed on February 10<sup>th</sup> under News Coverage in Media section of the company's website at [www.cornerstonepharma.com](http://www.cornerstonepharma.com).

#### **About CPI-613**

CPI-613 is the lead drug candidate from Cornerstone's proprietary AEMD platform. Cornerstone's AEMD drug platform disrupts the essential "bioenergetic" differences that support the growth and development of many types of cancer cells. In the case of CPI-613, the compound has been shown to selectively induce inhibition of pyruvate dehydrogenase (PDH) and alpha ketoglutarate dehydrogenase (KGDH), key mitochondrial enzymes involved in cancer cell metabolism in vitro. Disruption of PDH and KGDH function cuts off the tumor's energy supply, culminating in cell death. CPI-613 is currently being evaluated in Phase I, I/II, and II human clinical trials in solid tumors and hematological malignancies.

#### **About Cornerstone Pharmaceuticals, Inc.**

Cornerstone Pharmaceuticals, Inc. is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. The company's unique approach to targeting cancer metabolism has led to two distinct technology platforms: altered energy metabolism directed, or AEMD, compounds and an Emulsiphan lipid nanoemulsion based drug delivery system. [www.cornerstonepharma.com](http://www.cornerstonepharma.com).



###

This release contains forward-looking statements. These statements relate to future events or the company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.